6.21
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
What analysts say about NeoGenomics Inc. stockUnmatched profit potential - Autocar Professional
What drives NeoGenomics Inc. stock priceRapidly expanding wealth - jammulinksnews.com
NeoGenomics Inc. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
Is NeoGenomics Inc. a good long term investmentBreakthrough wealth creation - Jammu Links News
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy - Nature
Neogenomics Shares Plunge 7.14% Amid Earnings Woes - AInvest
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know - Yahoo Finance
Pathological Examination Market Gaining Momentum in Cancer - openPR.com
NeoGenomics (NASDAQ:NEO investor five-year losses grow to 81% as the stock sheds US$71m this past week - simplywall.st
Why NeoGenomics Inc. stock attracts strong analyst attention200 Percent Profit Outlook - beatles.ru
Q1 Earnings Highlights: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Testing & Diagnostics Services Stocks - Yahoo Finance
NEO Stock Price and Chart — NASDAQ:NEO - TradingView
NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know - Yahoo Finance
Press Release: NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 - 富途牛牛
NeoGenomics (NEO): A Contrarian Play on Turnaround and Undervaluation - AInvest
The past five years for NeoGenomics (NASDAQ:NEO) investors has not been profitable - Yahoo Finance
NeoGenomics Announces Chief Executive Officer Appointment - ACCESS Newswire
Here’s Why NeoGenomics (NEO) Sold Off in Q1 - Insider Monkey
NeoGenomics To Participate In Fireside Chat At Stephens 21st Annual Investment Conference - ACCESS Newswire
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 - Bluefield Daily Telegraph
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care - The Joplin Globe
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - Yahoo Finance
NeoGenomics' Market Cap Drops To US$954m Leaving Insiders With Losses - simplywall.st
NeoGenomics Requests to Dismiss Class Action Filed by Investors - TradingView
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021 - ACCESS Newswire
Investor Calendar Invites You to the NeoGenomics Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Tuesday March 1, 2016 - ACCESS Newswire
NeoGenomics at William Blair Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
NeoGenomics at William Blair Conference: Strategic Growth and Innovation - Investing.com Australia
Where are the Opportunities in (NEO) - news.stocktradersdaily.com
Cancer Tumor Profiling Market Rises with Demand - openPR.com
Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com
Fort Myers-based NeoGenomics to unveil new cancer diagnostics at ASCO 2025 - Gulfshore Business
NeoGenomics unveils new oncology diagnostics at ASCO 2025 By Investing.com - Investing.com South Africa
Neogenomics director Kelly buys $38,000 in common stock - Investing.com Australia
Neogenomics director Kelly buys $38,000 in common stock By Investing.com - Investing.com Nigeria
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025 - BioSpace
NeoGenomics unveils new oncology diagnostics at ASCO 2025 - Investing.com
NeoGenomics Approves Key Proposals at Annual Meeting - TipRanks
D. E. Shaw & Co. Inc. Trims Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
BNP Paribas Financial Markets Sells 35,979 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of “Hold” from Analysts - Defense World
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):